Foghorn Therapeutics (FHTX) Investor presentation summary

Strategic partnerships and financial position

• Entered a major collaboration with Lilly, including $380 million upfront and potential for $1.3 billion in milestones, with a 50/50 U.S. economic split on two lead programs and tiered ex-U.S. royalties.

• Maintains $183.6 million in cash and equivalents as of March 31, 2026, with a projected cash runway into the first half of 2028.

Pipeline and innovation

• Focuses on chromatin biology, targeting up to 50% of tumors and addressing over 500,000 patients with current pipeline.

• Lead asset FHD-909, a selective SMARCA2 inhibitor, is in Phase 1 for SMARCA4-mutant cancers, partnered with Lilly.

• Additional programs include selective degraders for CBP, EP300, and ARID1B, with IND-enabling studies anticipated in 2026.

Clinical and preclinical data highlights

• FHD-909 monotherapy and combinations show strong in vivo efficacy and tumor regression in SMARCA4-mutant NSCLC models.

• Combination of FHD-909 with anti-PD1 or KRAS inhibitors demonstrates synergistic and durable responses, including immune memory formation.

• Selective CBP and EP300 degraders show potent anti-tumor activity and improved tolerability in preclinical models of breast, bladder, gastric, hematological, and prostate cancers.